On January 5, 2024, PMV Pharmaceuticals, Inc. announced the appointment of Michael Carulli as Chief Financial Officer of the Company, to serve in such capacity until a successor is duly appointed and approved by the Company?s board of directors (? Board?). The effective date of Mr. Carulli?s appointment was January 5, 2024.

On January 5, 2024, the Company also announced that Winston Kung, the Company?s current Chief Operating Officer (? COO?) and CFO, will transition from his role as COO and CFO, effective January 4, 2024. Mr. Kung will serve as an advisor to the Company through March 31, 2024 to assist in the transition of his duties.

Mr. Kung?s departure is not related to any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Carulli, 50, has served as the Company?s Senior Vice President of Finance since March 2023, and prior to that, as Vice President of Finance from May 2020 to March 2023. Prior to joining the Company, Mr. Carulli was at Celgene (now Bristol Myers Squibb), a global biopharmaceutical company, since 2010 where he held multiple positions, including most recently as Executive Director FP&A ?

Research & Development, and oversaw the financial and operational plans for the research and development organization. Combined, Mr. Carulli has over 20 years of financial management experience. Mr. Carulli received a B.S. in Marketing and Management from Siena College and a M.B.A. from the Fordham Gabelli School of Business.